Email Facebook Twitter

EXCLUSIVE: Robin Young, CEO, Amur Minerals #AMC talks long-term strategy

Member Info for SatellitePro

Send a private message to SatellitePro

Member Since: Wed, 9th Jun 2010

Number of Share Chat Posts (all time): 21
Number of Share Chat Posts (last 30 days): 0

Last Posted: 1 Aug '14

1 Aug '14

Let's hope it keeps going!
1 Feb '12

that there seems to be so little interest in this share which promises to be a block-buster in the future!
31 Jan '12

rise today. lets hope it can be sustained.
13 Oct '11

Looks like Barclays got it wrong - for now at least
10 Aug '11

CE Mark has been awarded for RB to sell its Durex brand 'viagra' condom. This will be a market leading condom imho with huge potential for increase in market share for RB. See also FUM discussion boards.
22 Jun '11

Up over 25% since my post below on 10 May. Looks like it was a good short term bet too!
20 Jun '11

There is still time to buy before the final approval but this is probably the last opportunity. Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, is pleased to announce it has been informed that the relevant Notified Body is satisfied that all outstanding points in the regulatory dossier for CSD500 have been resolved and has been recommended to their Review Panel for approval. The Panel’s approval process typically takes a month and is already underway. A further statement will be made in the coming weeks regarding the issue of the CE mark certificate. The CE mark certificate will enable CSD500 to be marketed and sold within 29 European territories and a number of other non-European territories that recognise the CE mark process. Reckitt Benckiser plc, makers of the Durex® branded condom have exclusive global rights to CSD500.
10 May '11

They have produced a fairly solid performance over the past few years - good long term bet IMHO.
7 May '11

A year of substantial growth has positioned the business well on its three year growth plan.
 Revenue increased by 37% from £15.1 million to £20.8 million.
 Profit from continuing operations (excluding loss on disposal of available-for-sale asset) increased from £0.2m to
 Orders booked in the year increased by 64% from £13.3 million to £21.8 million.
 Re-financing exercise completed with all borrowings now supported by trade.
 Pipeline of new business opportunities continued to be strengthened during the year and into 2011.
 £3.9 million received following capital reduction and subsequent disposal of Evervision.
 Proposed repayment to shareholders of 5p per share consisting of a 4p Capital Reduction and a 1p Dividend.
 Interim dividend of 0.1p per share paid and a final dividend of 0.2p proposed.

Sign up for Live Prices
Top Recommended
Hot Chat Topics
Top recommended posters in the last 30 days

Member Login

Forgotten your password?


Don't have an account? Click here to Register Free!

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk.
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.